Evidence map›Paper›PMID 28148632›Full record

Trial reportNeurology2017

Serum neurofilament is associated with progression of brain atrophy and disability in early MS.

Jens Kuhle, Bardia Nourbakhsh, Donna Grant, Steve Morant, Christian Barro, Özgür Yaldizli, Daniel Pelletier, Gavin Giovannoni, Emmanuelle Waubant, Sharmilee Gnanapavan

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 104 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 1 pooled it
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00501943 phase2completednot on this map

Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis

TypeinterventionalSponsorUniversity of California, San FranciscoRan2006 to 2012Enrolled43ConditionsMultiple SclerosisArmsAvonex (Interferon beta 1a), Riluzole, Placebo
NCT04593082 active not recruitingnot on this mapstarted 2021, after this paper: background citation

Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis.

TypeobservationalSponsorUniversity of VirginiaRan2021 to 2027Enrolled116ConditionsMultiple Sclerosis
3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Jens KuhleFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK. jens.kuhle@usb.ch.
Bardia NourbakhshFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Donna GrantFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Steve MorantFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Christian BarroFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Özgür YaldizliFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Daniel PelletierFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Gavin GiovannoniFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Emmanuelle WaubantFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
Sharmilee GnanapavanFrom Neurologic Clinic and Policlinic (J.K., C.B., O.Y.), Departments of Medicine, Clinical Research, and Biomedicine, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (B.N., E.W.), University of California San Francisco; Department of Neuroimmunology (D.G.), Queen Square, Institute of Neurology, London; independent statistician (S.M.), Haddenham, Bucks, UK; Department of Neurology (D.P.), University of Southern California, Los Angeles; and Department of Neuroscience and Trauma (G.G., S.G.), Queen Mary University of London, UK.
University College London · GBInstitute of Neuroimmunology of the Slovak Academy of Sciences · SKNational Hospital for Neurology and Neurosurgery · GBUniversity of California, San Francisco · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate a potential effect of riluzole on serum neurofilaments (Nf) compared to placebo and the relationship between longitudinal clinical and MRI outcomes and serum Nf levels.

methodsSerum samples were obtained from participants enrolled in a randomized double-blind trial of neuroprotection with riluzole vs placebo as an add-on to weekly interferon-β (IFN-β)-1a IM initiated 3 months after randomization. Nf measurements were performed by ELISA and electrochemiluminescence immunoassay.

resultsLongitudinal serum samples were available from 22 riluzole and 20 placebo participants over 24 months. There was no observed treatment effect with riluzole. Nf light chain (NfL) levels decreased over time (

conclusionsOur findings support the potential value of serum NfL as a marker of neuroaxonal injury in early multiple sclerosis. Its reduction over time could represent regression to the mean, or a possible treatment effect of IFN-β-1a. The association with whole brain atrophy and the formation of acute white matter lesions has relevant implications to use serum NfL as a noninvasive biomarker of the overall consequences of brain damage and ongoing disease activity. CLINICALTRIALSGOV IDENTIFIER: NCT00501943.

Indexed as

Adjuvants, ImmunologicAdultAtrophyBiomarkersBrainDisability EvaluationDisease ProgressionDrug Therapy, CombinationFemaleFollow-Up StudiesHumansInterferon beta-1aMagnetic Resonance ImagingMaleMultiple Sclerosis, Relapsing-RemittingNeurofilament ProteinsAdjuvants, ImmunologicBiomarkersInterferon beta-1aneurofilament protein Hneurofilament protein LNeurofilament ProteinsNeuroprotective AgentsRiluzole

Identifiers

PMID28148632
PMCPMC5331872
OpenAlexW2584007915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.